Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sarah Curci

Physician Assistant, Medical Sewell, NJ Physician Assistant

NPI 1821576661 CMS profile 10620888

150 Delsea Dr Ste B, Sewell, NJ 08080

Open in the dashboard

General payments

$8,462

572 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Curci of Sewell, NJ is reported in the CMS Open Payments database as having received $8,462 across 572 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,657 111
2024 General $1,333 97
2023 General $2,775 172
2022 General $1,716 118
2021 General $981 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Curci
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Sarah Curci were reported at $1,657. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Sarah Curci Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $981 $156 $41–$563 $132
2022 $1,716 $185 $55–$649 $149
2023 $2,775 $199 $58–$717 $160
2024 $1,333 $206 $62–$740 $164
2025 $1,657 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,647 128 payments
  2. Janssen Biotech, Inc. $1,434 90 payments
  3. Amgen Inc. $1,240 106 payments
  4. Novartis Pharmaceuticals Corporation $732 38 payments
  5. AstraZeneca Pharmaceuticals LP $410 20 payments
  6. UCB, Inc. $402 27 payments
  7. E.R. Squibb & Sons, L.L.C. $382 37 payments
  8. GlaxoSmithKline, LLC. $349 18 payments
  9. Pfizer Inc. $336 24 payments
  10. Horizon Therapeutics plc $258 25 payments
  11. Other $1,271 59 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,070 566 payments
  2. Education $392 6 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,245 74 payments
  2. RINVOQ $1,062 81 payments
  3. EVENITY $774 79 payments
  4. Prolia $703 73 payments
  5. COSENTYX $560 29 payments
  6. Cimzia $384 26 payments
  7. ORENCIA $382 37 payments
  8. SAPHNELO $367 17 payments
  9. SKYRIZI $355 27 payments
  10. BENLYSTA $336 17 payments
  11. Other $4,179 283 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

3,203

Median for Physician Assistant: 241

Drug cost

$1,339,198

Median for Physician Assistant: $4,110

Branded share of claims

18.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 30 $285,254
Cimzia (2 Pack) Certolizumab Pegol Brand 36 $239,886
Tremfya Guselkumab Brand 17 $225,877
Remicade Infliximab Brand 28 $212,044
Benlysta Belimumab Brand 28 $124,401
Xeljanz Xr Tofacitinib Citrate Brand 19 $108,989
Prolia Denosumab Brand 26 $46,076
Otrexup Methotrexate/Pf Brand 11 $18,745
Hydroxychloroquine Sulfate Generic 362 $18,185
Methotrexate Methotrexate Sodium Brand 253 $7,872

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$480,063

Of which drugs: $365,602

Medicare patients

285

Average age 72

Services billed

68,581

235 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Osteoporosis 52%
Depression 29%
Diabetes 23%
Ischemic heart disease 22%
Chronic kidney disease 18%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 17 42,800 $156,301
Injection, denosumab, 1 mg J0897 Office 60 4,560 $91,194
Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg J7320 Office 18 3,075 $13,662
Injection, methylprednisolone acetate, 1 mg J1010 Office 74 11,201 $1,103
Injection, methylprednisolone acetate, 40 mg J1030 Office 53 176 $825

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $181
$181 17 —
SKYRIZI
  • AbbVie, Inc. $148
$148 — —
RINVOQ
  • AbbVie, Inc. $147
$147 — —
ORENCIA
  • E.R. Squibb & Sons, L.L.C. $134
$134 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $70
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

572 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record